Evaluating effect of central subfield thickness, volatility on visual acuity in clinical trials for nAMD
Justis P. Ehlers, MD, dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.
Copernicus and Galileo trials: Effect of time since diagnosis on BCVA outcomes in CRVO
Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.
Hypersonic vitrectomy: Novel technology for vitreous removal
Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Sunir J. Garg, MD, FACS, explains how retinal surgeons can remove the vitreous gel with more efficiency.
Carl Regillo, MD, outlines latest results of KSI-301 clinical trial
While the DAZZLE trial failed to meet its primary endpoint, KSI-301 demonstrated good initial visual gains and anatomic effects as well as positive durability.
YOSEMITE and RHINE trials yield durability, retinal fluid reduction, DME resolution with faricimab
In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.
At-home subcutaneous anti-VEGF injection for wet AMD, DME is safe, effective in Phase 1 trial
Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous anti-VEGF injection option in development for the treatment of wet AMD and DME.
Finding uveitis in the clinic: Imaging, tests to catch signs and symptoms
Yasha S. Modi, MD, discusses his best tips and tricks for finding and diagnosing infectious uveitis.
Study aims to identify cell types, specific genes in treating primary open angle glaucoma
Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.
Investigating the efficacy of targeting the Ang/Tie2 pathway with faricimab
Professor Anat Loewenstein, MD, discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular edema.
Amblyopia affects binocular vision, research suggests
The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.
EYP-1901 introduces treat-to-maintain paradigm for anti-VEGF therapy
EyePoint Pharmaceuticals hopes to usher in a new paradigm of retinal eye disease treatments with their candidate EYP-1901.
Cell therapy trial may lead to treatment for dry AMD, geographic atrophy
The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).
"Focus on Child Eye Health" presented by International Agency for the Prevention of Blindness
The International Agency for the Prevention of Blindness (IAPB) recently announced an expansion of their ‘Focus on Glaucoma’ and ‘Focus on Diabetes’ series with their new ‘Focus on Child Eye Health’ series in partnership with CooperVision.
2 Clarke Drive Cranbury, NJ 08512